Concepts (118)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Receptors, AMPA | 5 | 2012 | 41 | 1.030 |
Why?
|
| Hirudins | 1 | 2024 | 9 | 0.920 |
Why?
|
| Antithrombins | 1 | 2024 | 16 | 0.900 |
Why?
|
| Peptide Fragments | 2 | 2024 | 349 | 0.880 |
Why?
|
| Thrombocytopenia | 1 | 2024 | 48 | 0.880 |
Why?
|
| Heparin | 1 | 2024 | 111 | 0.860 |
Why?
|
| Recombinant Proteins | 1 | 2024 | 692 | 0.780 |
Why?
|
| Anticoagulants | 1 | 2024 | 485 | 0.670 |
Why?
|
| alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid | 3 | 2012 | 6 | 0.560 |
Why?
|
| Protein Subunits | 3 | 2012 | 164 | 0.480 |
Why?
|
| Protein Multimerization | 3 | 2012 | 167 | 0.470 |
Why?
|
| Allosteric Regulation | 2 | 2012 | 69 | 0.390 |
Why?
|
| Cell Membrane | 2 | 2011 | 490 | 0.380 |
Why?
|
| Calcium | 2 | 2011 | 552 | 0.360 |
Why?
|
| Synaptic Transmission | 1 | 2012 | 151 | 0.360 |
Why?
|
| Meningeal Arteries | 1 | 2025 | 9 | 0.240 |
Why?
|
| Moyamoya Disease | 1 | 2024 | 11 | 0.230 |
Why?
|
| Drug Substitution | 1 | 2024 | 41 | 0.230 |
Why?
|
| Cerebral Revascularization | 1 | 2024 | 30 | 0.230 |
Why?
|
| Aneurysm, False | 1 | 2024 | 46 | 0.220 |
Why?
|
| Synapses | 3 | 2015 | 177 | 0.210 |
Why?
|
| Aneurysm, Ruptured | 1 | 2024 | 72 | 0.210 |
Why?
|
| Receptors, N-Methyl-D-Aspartate | 2 | 2012 | 76 | 0.190 |
Why?
|
| Embolization, Therapeutic | 1 | 2025 | 306 | 0.190 |
Why?
|
| After-Hours Care | 1 | 2021 | 8 | 0.180 |
Why?
|
| Time-to-Treatment | 1 | 2021 | 101 | 0.170 |
Why?
|
| Models, Molecular | 4 | 2012 | 1124 | 0.170 |
Why?
|
| Postoperative Complications | 2 | 2025 | 1133 | 0.170 |
Why?
|
| Intracranial Aneurysm | 1 | 2024 | 339 | 0.170 |
Why?
|
| Thrombectomy | 1 | 2021 | 206 | 0.160 |
Why?
|
| Neurilemmoma | 1 | 2018 | 11 | 0.150 |
Why?
|
| Sacrum | 1 | 2018 | 22 | 0.150 |
Why?
|
| Endovascular Procedures | 1 | 2024 | 570 | 0.150 |
Why?
|
| Robotic Surgical Procedures | 1 | 2018 | 96 | 0.130 |
Why?
|
| Treatment Outcome | 2 | 2024 | 5172 | 0.130 |
Why?
|
| Parvalbumins | 1 | 2015 | 10 | 0.120 |
Why?
|
| Interneurons | 1 | 2015 | 22 | 0.120 |
Why?
|
| Pituitary Neoplasms | 1 | 2015 | 23 | 0.120 |
Why?
|
| Granuloma | 1 | 2015 | 38 | 0.120 |
Why?
|
| Action Potentials | 1 | 2015 | 103 | 0.120 |
Why?
|
| Ultracentrifugation | 2 | 2011 | 28 | 0.120 |
Why?
|
| Nerve Net | 1 | 2015 | 93 | 0.110 |
Why?
|
| Endoscopy | 1 | 2015 | 97 | 0.110 |
Why?
|
| Electrophysiology | 2 | 2011 | 89 | 0.110 |
Why?
|
| Neurosurgical Procedures | 1 | 2015 | 94 | 0.110 |
Why?
|
| Humans | 12 | 2025 | 59410 | 0.110 |
Why?
|
| C-Reactive Protein | 1 | 2015 | 167 | 0.110 |
Why?
|
| Protein Conformation | 3 | 2011 | 763 | 0.110 |
Why?
|
| Ion Channels | 2 | 2011 | 87 | 0.110 |
Why?
|
| Protein Structure, Tertiary | 2 | 2012 | 663 | 0.110 |
Why?
|
| Protein Binding | 3 | 2012 | 1548 | 0.100 |
Why?
|
| Crystallography, X-Ray | 2 | 2011 | 422 | 0.100 |
Why?
|
| Protein Transport | 2 | 2011 | 394 | 0.100 |
Why?
|
| Binding Sites | 2 | 2012 | 871 | 0.100 |
Why?
|
| Nerve Tissue Proteins | 1 | 2015 | 420 | 0.100 |
Why?
|
| Receptors, Ionotropic Glutamate | 1 | 2011 | 3 | 0.100 |
Why?
|
| Glutamic Acid | 1 | 2012 | 98 | 0.090 |
Why?
|
| Alternative Splicing | 1 | 2012 | 120 | 0.090 |
Why?
|
| Amino Acid Sequence | 2 | 2011 | 1576 | 0.090 |
Why?
|
| Molecular Sequence Data | 2 | 2011 | 1973 | 0.090 |
Why?
|
| Sequence Homology, Amino Acid | 1 | 2011 | 357 | 0.090 |
Why?
|
| Middle Aged | 2 | 2024 | 16244 | 0.080 |
Why?
|
| Vaccines, Synthetic | 1 | 2009 | 68 | 0.080 |
Why?
|
| HIV Envelope Protein gp120 | 1 | 2009 | 139 | 0.080 |
Why?
|
| Male | 2 | 2024 | 27535 | 0.070 |
Why?
|
| Electrooculography | 1 | 2006 | 5 | 0.070 |
Why?
|
| Man-Machine Systems | 1 | 2006 | 4 | 0.070 |
Why?
|
| Neurons | 1 | 2012 | 859 | 0.070 |
Why?
|
| Pattern Recognition, Automated | 1 | 2006 | 61 | 0.060 |
Why?
|
| Hematoma, Subdural, Chronic | 1 | 2025 | 2 | 0.060 |
Why?
|
| Antibodies, Monoclonal | 1 | 2009 | 856 | 0.060 |
Why?
|
| Task Performance and Analysis | 1 | 2006 | 125 | 0.060 |
Why?
|
| User-Computer Interface | 1 | 2006 | 129 | 0.060 |
Why?
|
| Eye Movements | 1 | 2006 | 81 | 0.060 |
Why?
|
| HIV-1 | 1 | 2009 | 705 | 0.060 |
Why?
|
| Artificial Intelligence | 1 | 2006 | 166 | 0.050 |
Why?
|
| Incidence | 1 | 2025 | 1238 | 0.050 |
Why?
|
| Chicago | 1 | 2021 | 25 | 0.050 |
Why?
|
| Hospitals, Community | 1 | 2021 | 71 | 0.040 |
Why?
|
| Emergencies | 1 | 2021 | 114 | 0.040 |
Why?
|
| Young Adult | 2 | 2021 | 4316 | 0.040 |
Why?
|
| Thrombolytic Therapy | 1 | 2021 | 180 | 0.040 |
Why?
|
| Academic Medical Centers | 1 | 2021 | 315 | 0.040 |
Why?
|
| Peritoneal Cavity | 1 | 2018 | 31 | 0.040 |
Why?
|
| Animals | 2 | 2015 | 19638 | 0.040 |
Why?
|
| Cardiovascular Diseases | 1 | 2025 | 820 | 0.040 |
Why?
|
| Skull Base Neoplasms | 1 | 2015 | 5 | 0.030 |
Why?
|
| Hormones | 1 | 2015 | 56 | 0.030 |
Why?
|
| Vision Disorders | 1 | 2015 | 59 | 0.030 |
Why?
|
| Animals, Newborn | 1 | 2015 | 230 | 0.030 |
Why?
|
| Risk Assessment | 1 | 2021 | 1912 | 0.030 |
Why?
|
| Time Factors | 1 | 2021 | 3573 | 0.030 |
Why?
|
| Female | 3 | 2021 | 30877 | 0.030 |
Why?
|
| Aged | 2 | 2021 | 13335 | 0.030 |
Why?
|
| Dimerization | 1 | 2012 | 146 | 0.030 |
Why?
|
| Molecular Dynamics Simulation | 1 | 2012 | 115 | 0.020 |
Why?
|
| Spectrometry, Fluorescence | 1 | 2011 | 90 | 0.020 |
Why?
|
| Adult | 2 | 2021 | 15757 | 0.020 |
Why?
|
| Ligands | 1 | 2012 | 420 | 0.020 |
Why?
|
| Aged, 80 and over | 1 | 2021 | 5094 | 0.020 |
Why?
|
| Risk Factors | 1 | 2021 | 5010 | 0.020 |
Why?
|
| Immunoglobulin Fab Fragments | 1 | 2009 | 35 | 0.020 |
Why?
|
| Mice, Knockout | 1 | 2015 | 1988 | 0.020 |
Why?
|
| X-Ray Diffraction | 1 | 2009 | 56 | 0.020 |
Why?
|
| Crystallization | 1 | 2009 | 97 | 0.020 |
Why?
|
| Cross Reactions | 1 | 2009 | 123 | 0.020 |
Why?
|
| Diabetes Mellitus, Type 1 | 1 | 2015 | 602 | 0.020 |
Why?
|
| Retrospective Studies | 1 | 2021 | 6000 | 0.020 |
Why?
|
| DNA Primers | 1 | 2009 | 291 | 0.020 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2009 | 448 | 0.020 |
Why?
|
| Sequence Analysis, DNA | 1 | 2009 | 397 | 0.020 |
Why?
|
| Disease Models, Animal | 1 | 2015 | 2063 | 0.020 |
Why?
|
| Prospective Studies | 1 | 2015 | 3095 | 0.020 |
Why?
|
| Base Sequence | 1 | 2009 | 1311 | 0.020 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2015 | 2037 | 0.020 |
Why?
|
| Adolescent | 1 | 2015 | 5921 | 0.010 |
Why?
|
| Mutation | 1 | 2011 | 2442 | 0.010 |
Why?
|
| Mice | 1 | 2015 | 10272 | 0.010 |
Why?
|